Quarterly report pursuant to Section 13 or 15(d)

Revenue Recognition - Disaggregation of Revenue (Details)

v3.22.2
Revenue Recognition - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Disaggregation of Revenue [Line Items]        
Total revenues $ 38,406 $ 25,453 $ 73,746 $ 43,485
Americas        
Disaggregation of Revenue [Line Items]        
Total revenues 3,614 5,844 7,347 10,773
EMEA        
Disaggregation of Revenue [Line Items]        
Total revenues 4,690 6,169 8,817 12,450
APAC        
Disaggregation of Revenue [Line Items]        
Total revenues 30,102 13,440 57,582 20,262
Product revenue        
Disaggregation of Revenue [Line Items]        
Total revenues 34,645 14,717 65,335 24,943
Research and development revenue        
Disaggregation of Revenue [Line Items]        
Total revenues 3,761 10,736 8,411 18,542
Performance Enzymes        
Disaggregation of Revenue [Line Items]        
Total revenues 36,530 21,585 69,629 35,815
Performance Enzymes | Americas        
Disaggregation of Revenue [Line Items]        
Total revenues 2,307 3,703 4,861 6,574
Performance Enzymes | EMEA        
Disaggregation of Revenue [Line Items]        
Total revenues 4,121 4,442 7,186 8,979
Performance Enzymes | APAC        
Disaggregation of Revenue [Line Items]        
Total revenues 30,102 13,440 57,582 20,262
Performance Enzymes | Product revenue        
Disaggregation of Revenue [Line Items]        
Total revenues 34,645 14,717 65,335 24,943
Performance Enzymes | Research and development revenue        
Disaggregation of Revenue [Line Items]        
Total revenues 1,885 6,868 4,294 10,872
Novel Biotherapeutics        
Disaggregation of Revenue [Line Items]        
Total revenues 1,876 3,868 4,117 7,670
Novel Biotherapeutics | Americas        
Disaggregation of Revenue [Line Items]        
Total revenues 1,307 2,141 2,486 4,199
Novel Biotherapeutics | EMEA        
Disaggregation of Revenue [Line Items]        
Total revenues 569 1,727 1,631 3,471
Novel Biotherapeutics | APAC        
Disaggregation of Revenue [Line Items]        
Total revenues 0 0 0 0
Novel Biotherapeutics | Product revenue        
Disaggregation of Revenue [Line Items]        
Total revenues 0 0 0 0
Novel Biotherapeutics | Research and development revenue        
Disaggregation of Revenue [Line Items]        
Total revenues $ 1,876 $ 3,868 $ 4,117 $ 7,670